 |
|
|
 |
BCIRG 004
Study: BCIRG 004
| Title | Clinical protocol for a phase II double-blind evaluation of G-CSF vs the optimal schedule of SC-70935 in patients with breast cancer receiving chemotherapy with docetaxel, doxorubicin and cyclophosphamide (TAC) | ||||||||
|
Sponsor |
Searle Research and Development (Pharmacia and Upjohn) | ||||||||
| Rationale | TAC is associated with a relatively high incidence of febrile neutropenia when given without prophylactic hematopoetic growth factor support. This study compared two compounds for the reduction of febrile neutropenia when given as prophylaxis. | ||||||||
| Design | TAC  |
 |
| ||||||
|
Number of Patients |
451 patients | ||||||||
| Status | Final Results Published | ||||||||
Paper and Poster: |
Click here to view poster | ||||||||
